There could be a “paradigm shift” in the treatment of Parkinson’s disease, with breakthrough tech set to help 150,000 UK citizens in 2023.
Thousands of people with Parkinson’s Disease may soon benefit from “breakthrough” technology which experts claim could lead to a “paradigm” shift in treatment.
NICE, the National Institute for Health and Care Excellence, is currently evaluating a continuous monitoring system for people with Parkinson’s known as PDMonitor. Created by medical device company PD Neurotechnology, the new technology could be used by the NHS as soon as next year.
It’s expected that PD Neurotechnology will submit information to NICE before a Committee meeting set for next summer. It’s at this meeting where the devices for remote continuous monitoring of people with Parkinson’s disease will be discussed.
NICE’s Diagnostic Assessment Programme is evaluating four medical devices – PDMonitor being just one of them.
Parkinson’s treatment technology
The company uses medical-grade wearable technology to track Parkinson’s motor symptoms automatically and on an ongoing basis. It enables physicians to tailor treatment plans based on a stream of objective data showing how patients experience symptoms in their day-to-day lives.
More than 150 physicians have already been trained to use PDMonitor, and
The technology is currently used in private or hospital practice by physicians and patients in the UK, as well as parts of Europe such as France, Austria, Germany, Italy, Spain, Sweden, Ireland, Greece and Cyprus. Over 150 physicians have already been trained to use PDMonitor.
A “paradigm” shift for Parkinson’s disease
Professor Ray Chaudhuri, Head of Parkinson’s Research at King’s College Hospital, who has been piloting PDMonitor with private patients since March 2022, comments: “Parkinson’s is the world’s second most common neurodegenerative disease and a significant cause of disability.
“Patients’ quality of life and disease progression strongly depend on the consistent, prompt staging of the disease and optimal timing and dosing of the prescribed therapy.”
“PDMonitor is supporting a paradigm shift in Parkinson’s care by improving the quality and timeliness of information physicians have to assess the disease.
“Monitoring patients at home, continuously while they conduct everyday activities, allows treatment decisions to be made more frequently and physicians to respond faster to changing symptoms.
“While you cannot reverse Parkinson’s, you can delay the deterioration of symptoms and possibly decrease the risk of falling. Optimising care means the disease progresses slower in time and the therapeutic window is kept open.”
Transformative, medical-grade technology
Nikos Moschos, founder of PD Neurotechnology said: “Today, most Parkinson’s treatment is informed by subjective patient diaries reviewed by physicians once or twice a year. We’ve changed the game by providing physicians with a stream of objective data showing disease progression in the real world.”
“Our transformative, medical-grade technology offers continuous monitoring, full symptom coverage and a holistic view of the patient. The majority of patients feel their health and quality of life stabilised or improved after using PDMonitor. This is data and AI at its finest.”
TheHill secures UK gov funding and Barclays support to help advance digital innovation
Real time data collection changes the game for the stroke patient pathway
Inside BT’s mission to boost NHS connectivity
UCB and Open Medical partnership will support Fracture Liaison Services
Radar Healthcare announces Aamal Medical partnership
Photodisinfectant: can light curb the antimicrobial resistance crisis?
Video games may help teens discuss mental health
Why it’s time to revisit workplace mental health initiatives and make them work for everyone
Innovations in self-diagnostics technology: Paving the way to a healthier future?
Telehealth solution revolutionising stroke care in Cardiff and Vale UHB
- News4 weeks ago
TheHill launches NHS Market Access Accelerator recruitment for 2024 programme
- News2 weeks ago
Why a leading healthcare CEO sees recombinant DNA as a metaphor for developing breakthrough technologies
- Medtech3 weeks ago
Surtex Instruments to unveil game-changing Infinex microsurgery instruments at MEDICA
- AI1 week ago
Humans make better cancer treatment decisions than AI, study finds